Hemogenyx Pharmaceuticals PLC Announces Half-Year Report

Rhea-AI Summary

Hemogenyx Pharmaceuticals has announced its interim results for the six-month period ending June 30, 2021. Highlights include the completion of CDX antibody development with a global pharmaceutical partner and an agreement with the University of Pennsylvania for HEMO-CAR-T clinical trials. The company received two US patents for antibody technologies and made progress on its CBR/COVID-19 project. Additionally, Hemogenyx raised £12 million in development capital through convertible debt, later replaced by equity capital. The company remains focused on advancing its product candidates towards clinical trials.

Positive

• Completed CDX antibody development with a global partner.
• Agreement with University of Pennsylvania for HEMO-CAR-T development.
• Two US patents approved for antibody technologies.
• Progress on CBR/COVID-19 project targeting viral pathogens.

Negative

• None.

Interim Results for the period ended 30 June 2021

LONDON, UK / ACCESSWIRE / September 30, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the StandardListed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2021.

All financial amounts are stated in GBP British pounds unless otherwise indicated.

Key Highlights

• Completed development phase of CDX antibody with global pharmaceutical company ("GlobalCo") - in negotiations to license GlobalCo's part in the intellectual property for future work on CDX projects
• Entered into agreement with University of Pennsylvania ("Penn") for development of HEMO-CAR-T towards and into clinical trials
• Two patents approved by US Patents & Trademarks Office relating to bi-specific and monoclonal antibodies (the latter following the period end)
• In vitro laboratory progress on CBR/COVID-19 project to programme immune cells to destroy viral pathogens (such as SARS-CoV-2) and malignant cancer-causing cells
• £12 million of development capital raised initially through issue of convertible debt - this was subsequently replaced by equity capital
• the Half Year Reporthas been preparedin accordance with International Accounting Standard 34 ‘Interim FinancialReporting'; and

Fuller details of these developments are contained in the Interim Management Report below.

Commenting on the outlook for Hemogenyx Pharmaceuticals, Sir Marc Feldmann, Chairman, said:

"The Board is very pleased with progress on the scientific front during 2021. While progress towards the next stage with GlobalCo on the CDX antibody is continuing, the Company has made very significant steps in relation to HEMO-CAR-T, and its efforts to combat viral pathogens such as COVID-19 are encouraging. As the focus in relation to COVID-19 moves towards improved treatments alongside vaccinations, the team's work could be of great importance. In all, the Company remains on track to attain the next substantial stage in its development. We will provide further updates to shareholders as we advance our product candidates toward clinical trials."

Interim Management Report

We are pleased to provide an update on the Company's activities over the six-month period ended 30 June 2021.

The focus of our development in the period under review was on continuing development of CDX antibodies for the treatment of Acute Myeloid Leukaemia ("AML") and on conditioning for bone marrow transplants, and on HEMO-CAR-T which is being developed to provide an alternative method of treating these conditions. In addition, the Company has continued its work on its CBR/COVID-19 project.

Click on or paste the following URL into your web browser to view announcement in full:

http://www.rns-pdf.londonstockexchange.com/rns/4531N_1-2021-9-29.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/666196/Hemogenyx-Pharmaceuticals-PLC-Announces-Half-Year-Report

FAQ

What are the interim results for Hemogenyx Pharmaceuticals (HOPHF) for the period ending June 30, 2021?

Hemogenyx Pharmaceuticals announced significant advancements in antibody development, clinical trial preparations, and patent approvals during the six-month period ending June 30, 2021.

What key developments did Hemogenyx Pharmaceuticals (HOPHF) achieve in 2021?

Key developments include completing CDX antibody development, entering an agreement with the University of Pennsylvania for HEMO-CAR-T, and obtaining two US patents for antibody technologies.

How much capital did Hemogenyx Pharmaceuticals (HOPHF) raise in the interim period?

Hemogenyx Pharmaceuticals raised £12 million in development capital through the issuance of convertible debt, which was later replaced by equity capital.